First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer
Abstract Background Lung cancer is a malignant carcinoma which has the highest morbidity and mortality in Chinese population.Gefitinib, a tyrosine kinase (TK) inhibitor of epidermal growth factor receptor (EGFR), displays anti-tumor activity.The present data 5th marine division patch regarding first-line treatment with single agent gefitinib agains